Home>Topics>Stocks>Lexicon Pharmaceuticals

Lexicon Pharmaceuticals LXRX

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Premarket Gainers / Losers

      Headlines

      Wed, 9 Jul 2014

      Gainers: ACST +16% . LXRX +13% . NQ +9% . USU +9% . AAL +6% . TXMD +5% . CAMT +5% . Losers: GIMO -33% . TCS -15% . PT -7% . Post your comment!

    2. Lexicon hires former Eisai exec to be CEO

      Headlines

      Mon, 7 Jul 2014

      Lonnel Coats, most recently the head of Japanese pharma giant Eisai's U.S. unit, has been named Lexicon's ( LXRX ) new CEO, effective today. Coats' hiring comes 6 months after Lexicon announced (along with huge job cuts) CEO Arthur Sands is leaving. Post your comment!

    3. New Morningstar Analyst Report for Lexicon Pharmaceuticals Inc

      Stock Reports

      Fri, 27 Jun 2014

      background in cardiovascular disease and endocrinology, which is critical for the firm's LX4211 program. Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising

    4. Morning Star Ratings

      Commentary

      Wed, 7 May 2014

      I guess I should address this to Morning Star but don't find a way. My question is how can you cover in analysis a stock such as LXRX with 149 employes and not cover in your analysis a stock such as HLS, makes me wonder about how you pick your stocks to analyse. Jack

    5. lxrx not for now.

      Commentary

      Fri, 4 Apr 2014

      Despite a pipeline, lexicon pharma does not look cheap. At a valuation today of nearly 900 million, and an expensive road to drug approval, we should all expect continuing dilution of this equity. To my mind, the only reason to invest is for a catalyst gap up. Their diabetes drug looks intriguing,

    6. M* 5 Star Stocks

      Commentary

      Sat, 22 Mar 2014

      the criterion of "5 stars." I only got 6 stocks, none of them were familiar to me. Can this be right? Alumina AWCMY Buenaventure Mining BVN Fiat Group FIATY Lexicon Pharmaceuticals LXRX Petroleo Brasileiro SA Petrobras ADR BPR Posco PKX

    7. LXRX . Morningstar rating change

      Commentary

      Fri, 7 Feb 2014

      Morningstar rating change from 4-5 Stars. Does anyone buy or sell, based on M rating changes?

    8. Lexicon's Staff Cut and CEO Exit Reflect High Costs of Diabetes Drug Development

      Commentary

      Mon, 13 Jan 2014

      Lexicon Pharmaceuticals announced that longtime CEO and cofounder Arthur Sands plans to depart the firm, and that it will cut 45% of its workforce

    9. Lexicon's 2Q Results In Line With Our Expectations; Key Catalysts Remain in 2013

      Commentary

      Tue, 30 Jul 2013

      Lexicon Pharmaceuticals LXRX reported second-quarter results that put it on track to meet our forecast for the year, and we're maintaining our $3.50

    10. Lexicon's 4211 Looks Strong in Midstage Trial, We Expect Partner and Late-Stage Trials in 2013

      Commentary

      Mon, 25 Jun 2012

      Lexicon LXRX has released data from a Phase 2b study of LX4211, and we're maintaining our fair value estimate as we expect the firm to move

    « Prev1234Next »
    Content Partners